Austin, TXNCT06523439Now EnrollingIRB Ready

Major Depressive Disorder Clinical Trial in Austin, TX

Access cutting-edge major depressive disorder treatment through this clinical trial at a research site in Austin. Study-provided care at no cost to qualified participants.

Sponsored by University of Texas at Austin

Quick Self-Assessment

See if you qualify for this Austin location

Preparing your pre-screening questions…

Expert Care in Austin

Access major depressive disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related major depressive disorder treatment provided free

Apply for This Austin Location

Check if you qualify for this major depressive disorder clinical trial in Austin, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Austin

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Austin site if eligible
  4. 4Begin participation

About This Major Depressive Disorder Study in Austin

This is a single-site open-label clinical trial of the Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) protocol. The goal of this clinical trial is to learn if a new form of transcranial magnetic stimulation (TMS)-known generally as accelerated intermittent theta burst stimulation (aiTBS) and specifically as SAINT®-is effective as a first-line therapy in treating adolescents aged 14-19 years-old in their first episode of depression who have not undergone a full course of depression treatment prior to starting the trial and who remain antidepressant-free throughout the trial. The main questions this trial aims to answer are: * Does SAINT® relieve symptoms of depression as a first-line therapy in adolescents? * Is SAINT® a feasible option as a first-line treatment for adolescent depression? Researchers will measure the depression symptoms in adolescent participants before and after SAINT®. Parents of the adolescent participant will also participate in the study providing information about their experience and preference for TMS as a first-line treatment. Adolescent participants will: * Remain antidepressant-free throughout the study period of 6-7 weeks. * Receive an MRI of their head for precision targeting * Receive 5 days of aiTBS (SAINT®)

Sponsor: University of Texas at Austin

Who Can Participate

Inclusion Criteria

Male or Female, between the ages of 14 and 19 at the time of screening.
Able to read, understand, and provide written, dated assent and/or consent prior to screening. Proficiency in English sufficient to complete questionnaires and follow instructions during aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.
Diagnosed with Major Depressive Disorder (MDD) with a current Major Depressive Episode (MDE), according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5).
No prior major depressive episodes (MDEs) as determined by MINI-KID
HAMD-17 score of ≥20 at screening (Visit 1).
Treatment-naive as determined by the ATHF (no adequate antidepressant trials prior to screening defined as fewer than 4 weeks of antidepressant medication and fewer than 8 psychotherapy sessions in lifetime; willingness to taper medications and stop psychotherapy if recently started and within the window defined above.)
Access to ongoing psychiatric care before and after completion of the study.
In good general health, as evidenced by medical history.
Agreement to adhere to Lifestyle Considerations throughout study duration.

Exclusion Criteria

High-risk for suicide or active suicidal ideation (Suicidal Ideation Questionnaire- Junior \[SIQ-JR\] ≥ 31).
The presence or diagnosis of prominent anxiety disorder, or dysthymia (\>3 on SAPAS; \>10 on GAD-7)
Current severe insomnia (must sleep a minimum of 5 hours each night before stimulation)
Current mania or psychosis
Bipolar Affective Disorder and/or primary psychotic disorders.
Autism Spectrum disorder or Intellectual Disability
A diagnosis of obsessive-compulsive disorder (OCD)
Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal.
Urine screening test positive for illicit substances.
Any history of ECT (greater than 8 sessions) without meeting responder criteria
Recent (during the current depressive episode) or concurrent use of a rapid acting antidepressant agent (i.e., ketamine or a course of ECT).
History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure/epilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma.
Untreated or insufficiently treated endocrine disorder.
Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion)
Contraindications to MRI (ferromagnetic metal in their body).
Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
Depth-adjusted aiTBS treatment dose \> 65% maximum stimulator output (MSO)
Treatment with another investigational drug or other intervention within the study period.
Any other condition deemed by the PI to interfere with the study or increase risk to the participant.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Austin?

Yes, this clinical trial (NCT06523439) has an active research site in Austin, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Major Depressive Disorder Treatment Options in Austin, TX

If you're searching for major depressive disorder treatment options in Austin, TX, this clinical trial (NCT06523439) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Austin research site is actively enrolling participants for this clinical trial. You'll receive care from experienced major depressive disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all major depressive disorder clinical trials near you to find additional studies recruiting in your area.

More Depression Trials in Austin, TX

See all depression clinical trials recruiting in Austin — not just this study.

Browse Depression Trials in Austin →

Browse More Trials by Condition

Depression TrialsMajor Depressive Disorder TrialsAll Conditions →

Ready to Join in Austin?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Austin, TX